| General Information of Drug Metabolite (DM) (ID: DM001074) |
| DM Name |
Cabazitaxel metabolite M1
|
|
|
|
|
|
|
|
| Full List of Drug-Metabolizing Enzyme (DME) Related to This DM |
| DME(s) Producing This DM through Metabolism |
| DME Name |
DME ID |
Reactant |
Reaction |
Related Drug |
REF |
|
Cytochrome P450 2C8 (CYP2C8)
|
DME0018
|
| Oxidation - Hydroxylation |
Cabazitaxel
|
[1] |
|
Cytochrome P450 3A4 (CYP3A4)
|
DME0001
|
| Oxidation - Hydroxylation |
Cabazitaxel
|
[1] |
|
Cytochrome P450 3A5 (CYP3A5)
|
DME0012
|
| Oxidation - Hydroxylation |
Cabazitaxel
|
[1] |
|
|
|
|
|
|
|
|
|
|
|
|
|
| Full List of Drug(s) That Produce This DM By Metabolism |
| Cabazitaxel |
DR0252
|
Approved |
Breast cancer |
|
|
| References |
| 1 |
A phase I open-label study investigating the disposition of [14C]-cabazitaxel in patients with advanced solid tumors Anticancer Drugs. 2015 Mar;26(3):350-8. doi: 10.1097/CAD.0000000000000185.
|
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.
